Mereo BioPharma Group PLC
MREO
Company Profile
Business description
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Contact
One Cavendish Place
4th Floor
LondonW1G 0QF
GBRT: +44 3330237300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
39
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,794.10 | 18.10 | -0.21% |
| CAC 40 | 7,987.49 | 0.00 | 0.00% |
| DAX 40 | 24,307.92 | 357.35 | 1.49% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,323.75 | 128.38 | 1.26% |
| HKSE | 25,682.55 | 7.37 | 0.03% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,758.05 | 57.90 | -0.10% |
| NZX 50 Index | 12,942.98 | 180.06 | 1.41% |
| S&P 500 | 7,403.05 | 5.45 | -0.07% |
| S&P/ASX 200 | 8,566.60 | 15.00 | -0.17% |
| SSE Composite Index | 4,124.35 | 7.17 | -0.17% |